

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number
WO 01/42298 A1

(51) International Patent Classification⁷: C07K 14/00, (74) Agent: FUESS, William, C.; Fuess & Davidenas, Suite A61K 38/00 II-G, 10951 Sorrento Valley Road, San Diego, CA 92121 (US).

(21) International Application Number: PCT/US00/07380

(81) Designated States (*national*): AU, CA, JP.

(22) International Filing Date: 20 March 2000 (20.03.2000)

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(30) Priority Data:
09/454,223 9 December 1999 (09.12.1999) US

Published:
— *With international search report.*

(71) Applicant and

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventor: KORNBLUTH, Richard, S. [US/US]; 5415 Taft Avenue, La Jolla, CA 92037 (US).



A1

(54) Title: MULTIMERIC FORMS OF TNF SUPERFAMILY LIGANDS

WO 01/42298

(57) Abstract: A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and RANKL/TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF-collecting fusion proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members.

MULTIMERIC FORMS OF TNF SUPERFAMILY LIGANDS

5

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to a method for preparing soluble multimeric proteins consisting of more than three iterations of the same bioactive molecule using recombinant DNA technology.

The present invention particularly concerns a new method of producing multimeric fusion proteins involving the TNF superfamily (TNFSF) members as a fusion proteins with SPD, and more specifically, CD40L-SPD fusion proteins and useful modifications thereof.

Description of Related Art

Numerous proteins can be made using modern molecular biology techniques and used in diagnostic and therapeutic applications. Using recombinant DNA techniques, the DNA encoding a single amino acid chain is constructed and then introduced into a cell which manufactures the final protein. Some cells, especially bacteria like *E. coli*, lack the ability to properly fold the amino acid chains into the proper quaternary structure and they often fail to apply the necessary modifications (e.g., glycosylation and disulfide bond formation) that are needed for the protein to be bioactive and resistant to degradation *in vivo*. While most of these challenges can be met by expressing the amino acid chain in eukaryotic cells like yeast or mammalian cells *in vitro*, it is not always straightforward to express proteins that consist of two or more amino acid chains. In general, for multichain proteins, the single amino acid chains must associate together in some way either within the producer cell or subsequently after the

monomers are secreted from the producer cell. For artificially constructed molecules, the introduction into a single amino acid chain of an amino acid sequence which causes this chain-to-chain association can be an important step in producing multichain proteins.

5

One of the most widely used methods of causing two amino acid chains to associate is to conjoin, at the DNA coding level, segments from the protein of interest and a segment from a spontaneously dimerizing protein. The best example is to conjoin or fuse a protein with the Fc portion of immunoglobulin, 10 creating a dimeric Fc fusion protein (Fanslow *et al.*, *J. Immunol.* 136:4099, 1986). A protein of this type can be formed from the extracellular domain of a tumor necrosis factor receptor fused to Fc (termed etanercept and marketed as ENBREL®), which is effective in the treatment of rheumatoid arthritis. A second example is the construction of a fusion protein between the dimerizing 15 extracellular portion of CD8 with the extracellular portion of CD40L (Hollenbaugh *et al.*, *EMBO J.* 11:4313, 1992). Here, the dimerizing CD8 portion of the fusion protein helps to maintain the CD40L portion in the trimeric form needed for its bioactivity. A more recent example is the addition of an isoleucine zipper motif to CD40L, which permits the production of trimeric soluble CD40L 20 molecules (Morris *et al.*, *J. Biol. Chem.* 274:418, 1999).

The TNF superfamily (TNFSF) consists of an expanding number of proteins (see Table I) which are crucial for the development and functioning of the immune, hematological, and skeletal systems. TNFSF proteins are ligands for 25 a corresponding set of receptors of the TNF receptor superfamily (TNFRSF). All TNFSF members are expressed as Type II membrane proteins, with the exception of lymphotoxin-alpha which is produced as a secreted protein. However, soluble forms of several TNFSF proteins can be released from the cell surface by proteolytic cleavage, usually by specific metalloproteinases.

The production of soluble forms of TNFSF proteins has been an important step in the study of these proteins. Soluble TNFSF ligands can be used to study the activities of these proteins *in vitro* without the complexities in interpretation that result when cells or cellular membranes expressing TNFSF proteins are added. In addition, soluble forms of several TNFSF proteins have potential as therapeutic agents for human diseases. In particular, TNF- α has been extensively studied for the treatment of cancer and soluble CD40L is currently undergoing clinical trials to assess its antitumor effects.

10

To produce soluble forms of TNFSF proteins, either the membrane protein is expressed in a cell line possessing a protease capable of separating the TNFSF extracellular domain from the transmembrane domain or a truncated form of the TNFSF protein is produced which consists solely of the extracellular domain plus a signal sequence. In either case, certain soluble forms of TNFSF proteins are unstable in solution as simple homotrimers composed solely of the extracellular domain. For example, naturally solubilized TNF- α is labile under physiological conditions [Schuchmann, 1995 #129]. To solve this stability problem, chimeric proteins have been constructed according to one of four different design principles: (1) The extracellular portion of the TNFSF protein has been expressed fused to the dimeric portion of the immunoglobulin Fc fragment US Patent 5,155,027, Oct. 13, 1992, issued to, Andrzej Z. Sledziewski, et al. In the case of CD40L and OX40L, this yields a soluble molecule which is significantly less active than the native membrane form of this protein. (2) The extracellular portion of the TNFSF protein has been expressed with an antigenic tag (usually the FLAG motif) fused to its N-terminus [Mariani, 1996]. The addition of an antibody to the tag (e.g., anti-FLAG antibody) aggregates these proteins into a multimeric form. Crosslinking enhances activity on B cells. (3) The extracellular portion of the TNFSF protein has been expressed fused to the spontaneously

dimerizing extracellular portion of the CD8 molecule [Hollenbaugh, 1992]. In the case of CD40L, this creates a hexameric molecule [Pullen, 1999] which is likely formed by two CD40L trimers attached to three CD8 dimeric stalks. Despite this, the addition of an anti-CD8 antibody to crosslink the CD40L-CD8 fusion protein 5 yields a further enhancement of CD40L activity on B cells. (4) The extracellular portion of the TNFSF protein has been expressed fused to a trimerizing isoleucine zipper which maintains the overall trimeric structure of the protein [US Patent 5,716,805, Feb. 10, 1998, issued to Subashini Srinivasan et al. This soluble CD40L trimer or 'sCD40LT' is the form of that protein now being clinically 10 tested in humans for its anti-tumor effects.

Compounding the difficulties in producing stable forms of soluble TNFSF proteins are compromises in bioactivity. As exemplified by FasL, TNF, and CD40L, many of the soluble forms of these proteins lack the full range of 15 stimulatory activities displayed by the membrane forms of these molecules. For FasL, several groups have reported that naturally produced soluble FasL (generated by proteolytic cleavage from the membrane form) has a spectrum of activities that is distinctly different from the membrane form. Soluble FasL induces apoptosis in activated CD4+ T cells but not fresh, resting CD4+ T cells. 20 In contrast, both types of CD4+ T cells are killed by membrane FasL or a recombinant soluble form of FasL (WX1) that spontaneously aggregates into oligomers larger than a decamer. For TNF, T cell activation through stimulation of TNFR II, the 80 kDa receptor for TNF, is much greater with membrane TNF than soluble TNF. However, if soluble TNF is produced as a tagged protein and 25 crosslinked with an antibody against the tag, then it completely mimics the activities of membrane TNF [Schneider, 1998]. Finally, for CD40L, the stimulatory effects of a soluble form of this TNFSF protein are enhanced by crosslinking [Kehry, 1994] and yields an activity similar to membrane CD40L. For example, soluble CD40L-CD8 fusion protein requires crosslinking with a

antibody to CD8 in order to drive resting B cells to proliferate to a degree similar to membrane-bound CD40L.). Even more strikingly, although membrane-bound CD40L expressed on baculovirus-transduced SF9 insect cells is a strong B cell stimulus, small vesicles (10 - 1,500 nm) prepared from the membranes of these 5 cells are less stimulatory. However, ultracentrifugation of these vesicles creates aggregates which have the full activity of the original membrane CD40L protein. This indicates that B cells are more highly stimulated by a large surface of CD40L than they are by a smaller surface expressing this membrane ligand.

10 Taken together, the above reports suggest that, for some TNFSF/TNFRSF ligand/receptor pairs at least, it is essential to cluster receptors together for full signaling activity. By this interpretation, the efficacy of the membrane forms of FasL, TNF, and CD40L occurs because these ligands can move in the plane of the membrane toward the contact zone with a receptor-bearing responding cell, 15 thereby clustering ligated receptors to form a receptor-dense region of the membrane. This interpretation is further supported by experiments where crosslinking of a soluble TNFSF protein effectively mimics the activity of the membrane form of the protein [Scheider, 1998].

20 In all of the above examples, no more than three amino acid chains have been caused to associate together. There is a need to produce multimeric protein molecules where more than three amino acid chains are caused to associate into a single soluble molecular complex. An important example comes from studies of CD40L (also called CD154 or TNFSF5), which is a member of the TNF family of 25 molecules that are normally expressed as insoluble, cell membrane proteins. It has been shown that soluble homotrimers composed of the extracellular regions of CD40L, TNF, and FasL are not potently active on resting cells that bear receptors for these proteins. However, if these proteins are expressed with a tag on their ends (e.g., the FLAG peptide sequence) and then the trimers are extensively

crosslinked using an antibody to FLAG, full activity appears (Schneider *et al.*, *J. Exp. Med.* 187:1205, 1998). From this, it can be inferred that the soluble single-trimer forms of these molecules does not duplicate the multivalent interactions that normally occur when a receptor-bearing cell comes in contact with the
5 membrane of a cell expressing numerous ligand trimers on its surface. This distinction may be due to a need for receptor clustering for full signaling (Bazzoni and Beutler, *N. Engl. J. Med.* 334:1717, 1996), which in turn is only possible with a multimeric ligand engaging many receptors at the same time in a localized region of the cell membrane.

10

SUMMARY OF THE INVENTION

The present invention contemplates a method of preparing soluble, multimeric mammalian proteins by culturing a host cell transformed or transfected
15 with an expression vector encoding a fusion protein comprising the hub, body, and neck region of a collectin molecule and a heterologous mammalian protein.

In one embodiment, the heterologous mammalian protein comprises an extra cellular domain of a mammalian transmembrane protein; the resulting fusion
20 protein forms a multimer.

In another embodiment, the heterologous mammalian protein comprises a soluble protein such as a cytokine; the resulting fusion protein forms a multimer.

25 In another embodiment, sites of proteolytic degradation are included or removed from the fusion protein; the resulting fusion protein forms a multimer from which are cleaved single units at a rate made variable by the nature of the proteolytic digestion sites either included or excluded.

In yet another embodiment, special attention is given to the immunogenicity of the fusion protein by altering the junction between the two naturally occurring proteins from which it is made; the resulting fusion protein may be less or more able to elicit an immune response against itself, which could 5 lengthen its persistence or contribute to its immunological effectiveness.

A hybrid nucleotide sequence of no more than 1528 base pairs including a sequence defining a structural gene expressing a conjoined single strand of a multimeric TNFSF-SPD fusion protein, said structural gene having a nucleotide 10 base sequence selected from members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5 is disclosed by this invention. In one embodiment, the DNA segment the structural gene has a sequence expressing a single hybrid amino acid chain of TNFSF-SPD, the segment having a first SPD nucleotide base sequence of SEQ ID NO 1, from base 32 to base 799, and a 15 second sequence, expressing a portion of TNFSF stalk, selected from members of the group consisting of SEQ ID NO 1, from base 800 to base 1444, SEQ ID NO 3, from base 800 to base 1528, and SEQ ID NO 5, from base 800 to base 1441.

In another embodiment, a recombinant DNA molecule has vector 20 operatively linked to an exogenous DNA segment defining a structural gene expressing a single amino acid chain of TNFSF-SPD. This structural gene has a nucleotide base sequence selected from members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5, any functional equivalents and modifications thereof. There is also attached an appropriate promoter for driving 25 the expression of said structural gene in a compatible host organism. The organism can be *E. coli*, a yeast, a higher plant or animal.

Yet another embodiment contemplated by the invention is multimeric TNFSF-SPD fusion protein having a plurality of polypeptide trimers, a first

trimer consisting of peptide strands of members of the TNF superfamily (TNFSF) of ligands, and a second trimer strand from a collectin molecule, each first trimer conjoined to a second polypeptide trimer strand from a collectin molecule, wherein said ligand strand is substituted for native carbohydrate recognition domains (CRD) of the collectin molecules. The conjoined collectin strands are covalently bound in parallel to each other, forming a multimeric fusion protein comprising a plurality of trimeric hybrid polypeptide strands radiating from a covalently bound center hub of the molecule. The free end of each trimeric radiating strand has a TNFSF moiety attached. The TNFSF moiety is one selected from the group consisting of ligands LTA, TNF, LTB, and TNFSF4 to TNFSF 18 as shown in Table II, and their functional equivalents, and modifications thereof.

The invention also contemplates a method for preparing a CD40-SPD multimeric fusion polypeptide, including the steps of initiating a culture, in a nutrient medium, of prokaryotic or eucaryotic host cells transformed with a recombinant DNA molecule including an expression vector, appropriate for the cells, operatively linked to an exogenous DNA segment defining a structural gene for CD40-SPD ligand. The structural gene has a nucleotide base sequence of SEQ ID NO 1 from about base 32 to about base 1444. Thereafter, the culture is maintained for a time period sufficient for the cells to express the multimeric molecule.

Also contemplated is a method of producing a secreted, very large, biologically active, multimeric tumor necrosis factor superfamily ligand fusion protein chimera that is highly immunogenic and not readily diffusible. The steps for this method are as follows:

1. introducing into a host cell a first chimeric DNA construct including a transcriptional promoter operatively linked to a first secretory signal sequence,

followed downstream by, and in proper reading frame with a first DNA sequence encoding a polypeptide chain of a first TNFSF ligand requiring multimerization for biological activity. This sequence is joined to a second DNA sequence encoding a collectin polypeptide at the site where the collectin's CRD was
5 purposefully removed.

2. introducing into the host cell, a second DNA construct including a transcriptional promoter operably linked to a second secretory signal sequence followed downstream by, and in proper reading frame with, a third DNA sequence encoding a second polypeptide chain of a second TNFSF ligand , joined to a
10 fourth DNA sequence encoding a collectin polypeptide , wherein the collectin's CRD was purposefully removed, and then,

3. growing the host cell in an appropriate growth medium under physiological conditions to allow the secretion of a large multimerized polypeptide fusion protein, wherein the first polypeptide chain of a TNFSF-SPD
15 protein is bound by parallel bonding of the respective collectin domain trimer to the second polypeptide chain of a different TNFSF-SPD polypeptide trimer, and wherein the multimerized polypeptide fusion protein exhibits biological activity characteristic of both membrane-attached TNFSFs, and

4. isolating the biologically active, multimerized TNFSF-SPD polypeptide fusion from said host cell. The chimeric reactant compounds are humanized to guard against destruction by a potential human recipient's immune system.
20

A final method of preparing a multimeric TNFSF-SPD ligand fusion protein contemplated requires a) preparing a first DNA segment coding for a
25 strand of an exposed extracellular portion of TNFSF; b) preparing a second DNA segment coding for a collectin polypeptide strand, wherein the collectin's CRD domain of the strand has been removed; c) conjoining the first and second DNAs in proper reading frame, thereby creating a TNFSF-collectin DNA construct; d) inserting the construct into an expression vector system; e) introducing the vector

system into an appropriate cell in culture under suitable conditions; f) harvesting and purifying spent medium from the culture; and finally g) assaying for presence of multimeric TNFSF-collectin fusion protein.

5 A method for stimulating the immune response in potentially immunocompetent cells using multimeric TNFSF fusion proteins by contacting the cells with the multimeric TNFSF fusion proteins, causing the cells to proliferate, is also contemplated. The cells used may be resting B cells. There is also a method for increasing antigenicity of cells by contacting the cells with the
10 multimeric TNFSF fusion proteins. In this case, the cells may be tumor cells or HIV positive cells.

Other preferred embodiments contemplate the methods of preparation described above, wherein the host transformed is either a prokaryote, such as E. coli, a eukaryote, for example yeast, such as S. cerevisiae, or a higher plant, such as alfalfa or tobacco.
15

Still further embodiments and advantages of the invention will become apparent to those skilled in the art upon reading the entire disclosure contained
20 herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Structure of the CD40L-SPD fusion protein. The extracellular portion of the CD40L homotrimer, including its membrane-proximal stalk, was fused to the body of SPD. The N-terminus of SPD contains two cysteines which link the homopolymer together by disulfide bonds forming a hub. The trimeric collagenous stalk extend from the hub as a cruciate structure and end in a spontaneously trimerizing neck region. The amino acid domains in a single chain
25

of the CD40L-SPD are shown at the top. At the bottom is the tetrameric (four CD40L trimers) which is expected to form. In addition, the hub region of SPD can participate in stacking up to 8 or more cruciate forms into higher order aggregates.

5

Figure 2. Ion-exchange chromatography of murine CD40L-SPD. CHO cells expressing murine CD40L-SPD were grown in serum-free media, concentrated using a 100 kDa cutoff ultrafiltration membrane, and diafiltered into 50 mM bicine, pH 9.0, 1 mM EDTA. Using an FPLC system, the protein from 400 mL of media was applied to a Fractogel SO₃⁻ 650M column and eluted with a linear salt gradient. 3 mL samples were collected. Shown are curves for protein concentration (OD₂₈₀), conductivity as % 1 M NaCl in the buffer, and ELISA-detectable CD40L-SPD assayed at 1:100 dilution.

10

Figure 3. Size fractionation of murine CD40L-SPD by ultrafiltration.

CD40L-SPD is a 471 amino acid protein with a predicted molecular weight of 49,012 for each of the twelve component chains in the dodecamer (composed of four trimeric subunits). This does not include added carbohydrates. Therefore, the full dodecamer will have a molecular weight in excess of 600,000. However, from the literature on recombinant surfactant protein D made in CHO cells, it appears that some of the product will be in the form of trimers that are not part of a cruciate-formed dodecamer. To determine what percentage of CD40L-SPD was produced in a multimeric form, supernatant from the transfected CHO cells were passed through filters of different porosities (rated for their ability to retard globular proteins). An ELISA was used to detect the amount of CD40L-SPD (measured at multiple dilutions) that passed through the filter. As shown, about 90% of the protein is retained by a 300,000 kDa cut-off filter. This indicates that most of the protein is in the dodecameric form. In addition, the cruciate dodecamers of surfactant protein D can also stack on top of each other into even

15

20

25

higher molecular weight forms. This is the likely explanation for the small fraction of CD40L-SPD that is retained by the 1,000 kDa cut-off filter.

Figure 4. Activation of human B cells by human CD40L-SPD. Conditioned media from CHO cells expressing human CD40L-SPD was added to human B cells along with IL-4. In the left panel, the cells were stained with CyChrome-labeled anti-CD19 to identify B cells and PE-labeled anti-CD3 to identify T cells. As shown, most of the cells proliferating in the culture were CD19+ CD3- B cells. In the right panel, the cells were stained with CyChrome-labeled anti-CD19 to identify B cells and PE-labeled anti-CD80 (B7-1) to identify this co-stimulatory molecule. As shown, almost all of the B cells were induced by CD40L-SPD to express CD80.

Figure 5. Activation of murine B cells by murine CD40L-SPD. Murine CD40L-SPD was added to resting murine splenic B cells for a two day culture period. For the final 4 hours, the cultures were pulsed with ³H-thymidine, following which the cells were harvested and DNA synthesis was measured by scintillation counting. As shown, CD40L-SPD is nearly as effective as anti-IgM in promoting the proliferation of resting B cells.

20

Figure 6. CD40L-SPD stimulation of macrophage chemokine production. Conditioned media from CHO cells expressing human CD40L-SPD, an inactive mutant of human CD40L-SPD (T147N-CD40L-SPD), or murine CD40L-SPD (mCD40L-SPD) were added to cultures of human monocyte-derived macrophages. As a negative control, this media was heat-inactivated at 60 °C for 30 minutes. Also shown is a form of soluble CD40L (sCD40L) consisting of 149 amino acids from the extracellular domain of human CD40L (Peprotech) added at 1 μ g/mL. 24 hours later, supernatants were collected and assay for MIP-1 α by ELISA (R & D Systems). The weak activity of soluble single-trimer CD40L

(sCD40L) is apparent. In contrast, native human and murine CD40L-SPD strongly activated the macrophages to produce MIP-1 \square . In contrast, heat-inactivated CD40L-SPD was inactive. As expected, the inactive mutant, T147N-CD40L-SPD, also failed to stimulate macrophages, demonstrating that the CD40L portion and not the SPD portion of the protein was responsible for stimulating the macrophages.

Figure 7. Expression of RANKL/TRANCE-SPD production from CHO cells detected by ELISA. Antibodies against RANKL/TRANCE were used to construct an ELISA capable of detecting the RANKL/TRANCE protein. As shown, there was no background with the media control. Using a fusion protein between CD70 (CD27L or TNFSF7) and SPD, there was also no signal, indicating the specificity of the ELISA. However, using CHO cells transfected with an expression plasmid for CD70-SPD, immunoreactive secreted protein was clearly detectable. This demonstrates the generalizability of the method for expressing TNFSF members as fusion proteins with collectins such as SPD.

DESCRIPTION OF THE PREFERRED EMBODIMENT

1. Definition of Terms

20 **Multimeric:** As used herein the term multimeric refers to a multimer of a polypeptide that is itself a trimer (i.e., a plurality of trimers).

Functional Equivalent: Herein refers to a sequence of a peptide or polypeptide that has substantial structural similarity and functional similarity to another such sequence.

25 **Modifications:** Herein refers to point changes involving single amino acids, wherein the functionality is altered, without appreciably altering the primary sequence or primary structure of a peptide or polypeptide.

Amino Acid: All amino acid residues identified herein are in the natural L-configuration. In keeping with standard polypeptide nomenclature, J. Biol.

Chem., 243:3557-59, (1969), abbreviations for amino acid residues are as shown in the following Table of Correspondence:

5

TABLE OF CORRESPONDENCE

| | | <u>SYMBOL</u> | <u>AMINO ACID</u> |
|----|---|-----------------|-------------------|
| | | <u>1-Letter</u> | <u>3-Letter</u> |
| | | Y | Tyr |
| | | G | Gly |
| 15 | F | Phe | L-phenylalanine |
| | M | Met | L-methionine |
| | A | Ala | L-alanine |
| | S | Ser | L-serine |
| | L | Ile | L-isoleucine |
| 20 | L | Leu | L-leucine |
| | T | Thr | L-threonine |
| | V | Val | L-valine |
| | P | Pro | L-proline |
| | K | Lys | L-lysine |
| 25 | H | His | L-histidine |
| | Q | Gln | L-glutamine |
| | E | Glu | L-glutamic acid |
| | W | Trp | L-tryptophan |
| | R | Arg | L-arginine |
| 30 | D | Asp | L-aspartic acid |
| | N | Asn | L-asparagine |
| | C | Cys | L-cysteine |

It should be noted that all amino acid residue sequences are represented herein by formulae whose left to right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a bond to a radical such as H and OH (hydrogen and hydroxyl) at the amino- and carboxy-termini, respectively, or a further sequence of one or more amino acid residues up to a

total of about fifty residues in the polypeptide chain.

Base Pair (bp): A partnership of adenine (A) with thymine (T), or of cytosine (C) with guanine (G) in a double stranded DNA molecule.

5 **Constitutive promoter:** A promoter where the rate of RNA polymerase binding and initiation is approximately constant and relatively independent of external stimuli. Examples of constitutive promoters include the cauliflower mosaic virus 35S and 19S promoters described by Poszkowski et al., *EMBO J.*, 3:2719 (1989) and Odell et al., *Nature*, 313:810 (1985).

DNA: Desoxyribonucleic acid.

10 **Enzyme:** A protein, polypeptide, peptide RNA molecule, or multimeric protein capable of accelerating or producing by catalytic action some change in a substrate for which it is often specific.

15 **Expression vector:** A DNA sequence that forms control elements that regulate expression of structural genes when operatively linked to those genes.

15 **Expression:** The combination of intracellular processes, including transcription and translation undergone by a structural gene to produce a polypeptide.

20 **Insert:** A DNA sequence foreign to the rDNA, consisting of a structural gene and optionally additional DNA sequences.

20 **Nucleotide:** A monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (1' carbon of the pentose) and that combination of base and sugar is a nucleoside. When the nucleoside contains a phosphate group bonded to the 3' or 5' position of the pentose it is referred to as a nucleotide.

25 **Operatively linked or inserted:** A structural gene is covalently bonded in correct reading frame to another DNA (or RNA as appropriate) segment, such as to an expression vector so that the structural gene is under the control of the expression vector.

Polypeptide and peptide: A linear series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues.

Promoter: A recognition site on a DNA sequence or group of DNA sequences that provide an expression control element for a gene and to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene.

Inducible promoter: A promoter where the rate of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include light, heat, anaerobic stress, alteration in nutrient conditions, presence or absence of a metabolite, presence of a ligand, microbial attack, wounding and the like.

Spatially regulated promoter: A promoter where the rate of RNA polymerase binding and initiation is modulated in a specific structure of the organism such as the leaf, stem or root. Examples of spatially regulated promoters are given in Chua et al., *Science*, 244:174-181 (1989).

Spatiotemporally regulated promoter: A promoter where the rate of RNA polymerase binding and initiation is modulated in a specific structure of the organism at a specific time during development. A typical spatiotemporally regulated promoter is the EPSP synthase-3SS promoter described by Chua et al., *Science*, 244:174-181 (1989).

Temporally regulated promoter: A promoter where the rate of RNA polymerase binding and initiation is modulated at a specific time during development. Examples of temporally regulated promoters are given in Chua et al., *Science*, 244:174-181 (1989).

Protein: A linear series of greater than about 50 amino acid residues connected one to the other as in a polypeptide.

Recombinant DNA molecule: A hybrid DNA sequence comprising at least two nucleotide sequences not normally found together in nature.

RNA: Ribonucleic acid.

Selective Genetic marker: A DNA sequence coding for a phenotypical trait by means of which transformed cells can be selected from untransformed cells.

5 **Structural gene:** A DNA sequence that is expressed as a polypeptide, i.e., an amino acid residue sequence.

Synthetic promoter: A promoter that was chemically synthesized rather than biologically derived. Usually synthetic promoters incorporate sequence changes that optimize the efficiency of RNA polymerase initiation.

10 2. Introduction

This invention discloses the production of TNFSF proteins as multimeric (i.e., many trimers) ligands fused onto a trimeric, branched protein backbone.

Collectin molecules are ideal for this purpose because they are formed from many trimeric, collagenous arms linked to a central hub by disulfide bonds. Of the 15 collectins, pulmonary surfactant protein D (SPD) was chosen initially because it is a homopolymer encoded by a single gene, unlike C1q and surfactant protein A, which are composed of two different protein subunits. In addition, recombinant SPD has been successfully expressed *in vitro* in reasonable yield [Crouch, 1994], and a peptide containing the “neck” region of SPD was shown to spontaneously 20 trimerize in solution [Hoppe, 1994]. Consequently, extracellular domains of human and murine CD40L were substituted for the carbohydrate recognition domain of pulmonary surfactant D (SPD) to create a four-armed molecule (three peptide chains per arm) with CD40L at the end of each arm. This molecule is named CD40L-SPD. In addition, because SPD tends to stack into higher order 25 aggregates with up to 8 molecules associated at the hub [Crouch], even greater degree of multimerization can occur [Lu, 1993]. CD40L-SPD therefore mimics the expression of CD40L by an activated T cell in that it presents a multivalent complex similar to membrane-bound CD40L. While remaining soluble, CD40L-SPD equals membrane CD40L in its range of activities.

3. Construction of expression plasmids for CD40L-SPD.

cDNAs of exposed human and murine CD40L, removed from cell membranes, were cloned by PCR by well-known methods. Murine surfactant protein D was cloned by hemi-nested PCR from murine lung mRNA (Clonetech).

5 cDNA was prepared using Superscript II reverse transcriptase (Life Technologies, Gaithersburg, MD) and random hexamers as primers. PCR primer sequences were as follows (the underlined bases indicate restriction endonuclease sites for cloning into the vector):

| | | |
|----|--------------|--|
| 10 | mSPD5: | 5'-CTGACATGCTGCCCTTCTCATGC-3' |
| | mSPD3ext: | 5'-GGAGGCCAGCTGTCCCTCCAGCCTGTTGC-3' |
| | rmSPD5: | 5' GGGG <u>CTAGCGAATTCCACCAGGAAGCAATCTGACATGCTGCCCTTCTCT</u> CCATGC-3' |
| | CD40L/SPD3: | 5'-CTATCTTGTCCAACCTTCTATG/GCCATCAGGGAACAAATGCAGCTTC-3' |
| 15 | SPD/CD40L5: | 5'-AAAGCTGCATTGTTCCCTGATGGC/CATAGAAGGTTGGACA AGATAGAAG-3' |
| | CD40L3: | 5'- <u>GGGCTCGAGGTACCAG</u> TCTACATGCCTTGGAGTGATAAT-3' |
| | SPD/mCD40L5: | 5'-GAAAGCTGCATTGTTCCCTGATGGC/CATAGAAGATTGGATAAGGTCGAAG-3' |
| | mCD40L/SPD3: | 5'-CTTCGACCTTATCCAATCTTCTATG/GCCATCAGGGAACAAATGCAGCTTC-3' |
| | mCD40L3: | 5'- <u>GGGGGGTAC</u> CCCTGCTGCAGCCTAGGACAGCGCAC-3' |

20 Because the murine SPD sequence of the 5' untranslated region containing the ribosomal binding site was unknown when this work was started [Motwani, 1995], a primer (rmSPD5) was designed based on the available rat sequence [Shimizu, 1992] which extended the 5' end with rat sequence (shown in bold) along with an added Nhe I site (underlined).

25

4. Creation of the CD40L-SPD Fusions.

To create the CD40L-SPD fusions, overlap PCR was used. Murine SPD was amplified by nested PCR using mSPD5 and mSPD3ext for the first round of 30 cycles. The product was diluted 1:1,000 and 1 μ L was amplified for another

30 cycles using rmSPD5 and CD40L/SPD3, where the 3' half of CD40L/SPD3 is a reverse primer for SPD C-terminal to the neck region (deleting the CRD) and the 5' half of CD40L/SPD3 contains bases from the N-terminus of the extracellular portion of CD40L (immediately adjacent to the transmembrane region). Similarly, the CD40L plasmid was amplified with SPD/CD40L5 and CD40L3, which contains a Kpn I site (underlined). All of these PCRs were performed with Pfu cloned polymerase (Stratagene,) using hot start (Ampliwax, Perkin-Elmer) and the thermocycling program: 94 °C for 2.5 min; then 30 cycles of 94 °C for 10 sec, 43 °C for 30 sec, and 75 °C for 7 min.

10

To form the chimeric construct, 1 µL of a 1:1,000 dilution of gel-purified products from the above reactions was combined and amplified with rmSPD5 and CD40L3. Because Pfu polymerase did not consistently yield the expected 1.62 kb overlap product, AccuTaq LA DNA polymerase (Sigma) was used for this PCR, using the thermocycling program: 94 °C for 2.5 min; then 30 cycles of 98 °C for 20 sec, 43 °C for 30 sec, and 68 °C for 10 min. The resulting product was digested with Nhe I and Kpn I, gel-purified, and ligated into the Nhe I and Kpn I sites in the expression plasmid, pcDNA3.1(+) (Invitrogen, Carlsbad, CA). DH5 E. coli were transformed with the construct and plasmid DNA was purified either by double banding in ethidium bromide-CsCl gradients or by anion exchange resin (QIAgen). To form the T147N-CD40L-SPD construct, the same approach was used except that the CD40L coding region was taken from the expression plasmid for T147N-CD40L [Kornbluth]. The amino acid sequence at the junction between SPD and CD40L is ...KAALFPDG/HRRLLDKIE..., where the C-terminal portion begins the sequence for CD40L. To form mCD40L-SPD, a similar approach was taken except that primers SPD/mCD40L5, mCD40L/SPD3, and mCD40L3 were used for amplifications involving murine CD40L sequences. The amino acid sequence at the junction between SPD and murine CD40L is ...KAALFPDG/HRRLLDKVE..., where the C-terminal portion begins the sequence

for murine CD40L. Both DNA strands of each construct were sequenced to confirm that the constructs were correct. In other experiments, an entirely humanized construct, consisting of human CD40L fused to human SPD, was constructed (data not shown).

5

5. Construction of expression plasmid for murine RANKL/TRANCE (TNFSF 11).

Spleen cells from C3H/HeJ mice were stimulated with 5 μ g/ml concanavalin A and 10 ng/ml IL-2 (Sigma) for 8 hours (31). mRNA was isolated 10 using the Micro FastTrack kit (Invitrogen). cDNA was prepared using Superscript II reverse transcriptase (Life Technologies) and random hexamers as primers. PCR primer sequences were as follows (where the underlined bases indicate restriction endonuclease sites for cloning into the vector):

| | |
|-----------------|--|
| 5mRANKL-ext: | 5'-CATGTTCTGGCCCTCCTC-3' |
| 15 3mRANKL-ext: | 5'-GTACAGGCTCAAGAGAGAGGGC-3' |
| 5mRANKL-int: | 5'- <u>ATACTCGAGCGCAGATGGATCCTAAC</u> -3' |
| 3mRANKL-int: | 5'- <u>GGGGTTTAGCGGGCCGCTAATGTTCCACGAAATGAGTTC</u> -3' |

The extracellular portion of RANKL/TRANCE was cloned by nested PCR. 20 In the first round of PCR, 5mRANKL-ext and 3mRANKL-ext were used with Pfu cloned polymerase (Stragene) using the thermocycling program: 94 °C for 2.5 min; then 30 cycles of 94 °C for 10 sec, 50 °C for 30 sec, and 75 °C for 2 min. The product was diluted 1:1,000 and 1 μ L was amplified for another 30 cycles 25 using 5mRANKL-int and 3mRANKL-int, which contain an Xho I site and a Not I site respectively. The resulting product was digested with Xho I, blunt-ended with T4 DNA polymerase, then digested with Not I and gel-purified. The CD40L-SPD expression plasmid described above was digested with Msc I and Not I and gel purified. Then the RANKL/TRANCE sequence was ligated into this vector in frame with the SPD coding sequence. The amino acid sequence at

the junction between SPD and RANKL/TRANCE is
...KAALFPDG/RAQMDPNR..., where the N-terminal portion is from SPD and
the C-terminal portion is the extracellular sequence of RANKL/TRANCE. Both
DNA strands of each construct were sequenced to confirm that the constructs
5 were correct.

6. Stable transfection of DHFR-deficient CHO cells and amplification.

DG44 (a line of CHO-K1 cells deficient in dihydrofolate reductase (DHFR)) (32) and pCH1P (a plasmid containing the hamster DHFR minigene) (33) were gifts from Dr. Lawrence Chasin, Columbia University, New York, NY. DG44 cells were cultured in □-MEM consisting of ribo- and deoxynucleoside-free □-MEM (BioWhittaker, Walkersville, MD) supplemented with 200 □M L-glutamine, 10% fetal bovine serum (FBS) and 10 □g/ml each of adenosine, deoxyadenosine, and thymidine (Sigma). All cell cultures described were negative in a mycoplasma rRNA assay (Gen-Probe, San Diego). DG44 cells in six-well plates were transfected by the method of Okayama and Chen ((34) with 10 □g of expression plasmid and 0.05 □g of pCH1P (200:1 ratio). After two days, the transfected DG44 were trypsinized and transferred to 100 mm plates. At this point, the media was switched to □-MEM which differs from □-MEM in that dialyzed FBS (HyClone Systems, Logan, UT) was used and no nucleoside supplements 20 were added. Only cells containing the DHFR minigene were able to grow in □-MEM, and colonies were selected after 10 days, cloned using cloning rings, and transferred to 12.5 cm² flasks. Clones were selected for expansion using an ELISA to screen for the production of either murine or human CD40L (see below). Using the method described by Kingston *et al.* (35), escalating doses of methotrexate were used to amplify the 25 transfected genes over a period of 6-14 months until the cells grew well in 80 □M methotrexate. Each expressing clone was re-cloned once or twice more in order to select the highest expressing cells.

7. Preparation of human and murine CD40L-SPD in serum-free media.

30 Selected clones were adapted for growth in nucleoside-free UltraCHO media (BioWhittaker) supplemented with 50-100 µg/mL ascorbic acid and 50 µM

methotrexate (Sigma). The non-adherent population was further adapted for suspension growth in roller bottles. In some experiments, the cells were adapted from DMEM to CHO-S-SFM II media (Life Technologies) supplemented with ascorbic acid and 50 µg/mL L-proline.

5

8. **ELISA assay for human and murine CD40L-SPD.**

To assay for correctly folded CD40L, wells of a MaxiSorb 96-well plate (Nunc) were coated overnight at 4 °C with 50 µL of carbonate-bicarbonate, pH 9.40 buffer containing 0.5 µg/mL 24-31 anti-human CD40L MAb (Ancell) or 10 MR1 anti-murine MAb (Bioexpress, Lebanon, NH). Wells were blocked with 3% bovine serum albumin (BSA) in PBS. 100 µL samples were added to the wells either neat or diluted in a dilution buffer consisting of 1% BSA, 0.9 % NaCl, 50 mM Tris pH 7.40, and 0.1% peroxide-free Tween 20 (Sigma). After shaking for 2 h at 600 RPM, a plate washer was used to wash the plate four times with 0.9 % 15 NaCl, 50 mM Tris pH 7.40, and 0.1% peroxide-free Tween 20. Then, 100 µL of diluent buffer containing 1 µg/mL biotinylated 24-31 anti-human CD40L Mab (Ancell) or MR1 anti-murine CD40L Mab (Pharmingen, San Diego, CA) was added to each well and again shaken for 2 h. Following another four washes, 100 µL of diluent buffer containing 1 µg/mL of streptavidin-alkaline phosphatase 20 (Jackson) was added to each well and the plate was shaken for 1 hour. Lastly, after another four washes, color was developed for 10-20 min using 100 µL/well of BluePhos (Kierkegaard & Perry), stop solution was added, and the wells were read at 650 µm in a plate reader.

25

9. **Purification of human and murine CD40L-SPD.**

Conditioned UltraCHO media was filtered using a 0.2 µ PES filter unit (Nalgene) and stored at 4 °C for up to 3 months. A preliminary size fractionation was performed by ultrafiltration through a 100 kDa-cutoff 76 mm membrane (YM-100, Millipore) in a 400 mL stirred cell at 10 lbs/sq. inch pressure of argon.

Media was concentrated to about 10 mL, diluted to 100 mL with buffer, and again concentrated to 10 mL for a total of 3 cycles of ultrafiltration and buffer exchange. Buffer was 50 mM Bicine (Calbiochem), adjusted to pH 9.0 with NaOH (about 32 mM Na), and 1 mM EDTA to prevent the activity of any metalloproteinase. Using FPLC equipment (Amersham-Pharmacia), the concentrate was filtered through a 0.45 μ filter, placed into a 10 mL superloop, applied to a 10 X 30 mm column (HR10/30, Amersham-Pharmacia) packed with Fractogel SO₃⁻ 650M (EM Biosciences), and eluted at 0.5 mL/min at 4 °C with a linear gradient of 0-500 mM NaCl in buffer. As described by the manufacturer, the resolution of proteins on Fractogel SO₃⁻ is enhanced by using a long, thin column geometry. Fractions were collected and screened for human or murine CD40L by ELISA. Positive fractions were pooled, concentrated by ultrafiltration (CentriPrep-30, Millipore), filtered through a 0.45 μ filter, and applied to a Superose 6 column (Amersham-Pharmacia) in phosphate-buffered saline.

15

10. **Murine B cell cultures.**

C3H/HeJ mice were euthanized by CO₂ inhalation under a protocol approved by the Animal Subjects Committee of the San Diego VA Healthcare System. Splenocytes were isolated by centrifugation over Lympholyte-M (Accurate Chemical & Scientific Corp., Westbury, NY) and B cells were isolated by negative selection using anti-CD43 immunomagnetic beads (Miltenyi Biotec Inc., Auburn, CA). The resting B cells were suspended in Dulbecco's MEM with 10% FBS at a concentration of 1 X 10⁶/mL, and 100 μ L was added to the wells of 96-well flat-bottomed plates. 100 μ L of dilutions of murine CD40L-SPD in media or media alone were added to the wells, which were incubated in 8.5% CO₂ at 37 °C for 48 hours. Then, 0.5 μ Ci/well of ³H-thymidine was added to each well, and the cells were collected 4 h later onto glass fiber filters using an automated cell harvester. A scintillation counter was used to determine the incorporated radioactivity.

11. **Human B cell cultures.**

Venous blood from consenting subjects was used as a source of human B cells under a protocol approved by the UCSD Institutional Review Board. Blood was collected into syringes containing 5 U/mL heparin and peripheral blood mononuclear cells (PBMC) were isolated by centrifugation over Ficoll-hyphaque. The cells were suspended at 2×10^5 /mL in RPMI 1640 containing 200 μ M L-glutamine, 10% FBS, 0.832 μ M cyclosporin A (Sigma), and 25 ng/mL human IL-4 (R & D Systems) and incubated in 5% CO₂ at 37 °C as described by Schultze *et al.* (36). At intervals, the cells were stained with CyChrome-conjugated anti-CD19 and PE-conjugated anti-CD80 (B7-1) monoclonal antibodies (Pharmingen) and analyzed by flow cytometry.

12. **Human monocyte-derived macrophage and dendritic cell cultures.**

As previously described [Kornbluth], monocytes were isolated from PBMC by adherence to fibronectin-coated plates, plated into 48-well plates, and then cultured in RPMI1640 containing 200 μ M L-glutamine and 10% autologous serum for 7-10 days. Monolayers of the matured cells (about 2×10^5 /well), termed monocyte-derived macrophages or MDM, were then washed in media and cultured in 1 mL/well RPMI1640 containing 200 μ M L-glutamine and 10% heat-inactivated FBS. Alternatively, dendritic cells (DC) were formed from monocytes by adding GM-CSF and IL-4 to the culture media, and the resulting DC were used 6 days later. Preparations of CD40L-SPD were added to the wells as indicated. As a positive control, 100 ng/mL bacterial lipopolysaccharide (LPS) from *E. coli* 0111:B4 (Calbiochem) was added. Supernatants were collected 24 h later and analyzed for cytokine content using ELISA (R & D Systems).

Example 1.

Design principles in constructing collectin-TNFSF member fusion proteins.

To express CD40L and other TNFSF members as stable, multimeric

proteins, the coding region of the extracellular, C-terminal portion of CD40L was joined in-frame to the collectin, surfactant protein D (SPD). The N-terminus of SPD contains two cysteines which form the disulfide bonds necessary for the 4-armed cruciate structure of the overall molecule [Brown-Augsburger, 1996 #506].

5 C-terminal to these cysteines in SPD is a long triple-helical collagenous "stalk" which ends in the "neck" region that promotes the trimerization of each arm of the structure. Immediately after this neck region, the coding sequence for the extracellular portion of CD40L was added, in place of the carbohydrate recognition domain (CRD) of SPD. The collectins were chosen as the framework

10 for the multimeric construct because of their multi-subunit structure and the trimeric nature of their stalk regions. Appropriateness of replacing the CRD of a collectin with the extracellular region of a TNFSF member is further supported by structural studies of the two protein families. An analysis of the CRD crystal structure of another collectin, ACRP30, indicated that it was structurally

15 superimposable upon the crystal structures of the extracellular regions of CD40L, TNF, and Fas [Shapiro, 1998]. The successful expression of the collectin-TNFSF fusion protein, CD40L-SPD, indicates that other TNFSF members (Table I) could be conjoined to SPD in a similar manner and that other collectins besides SPD (Table II) could be used as a protein framework instead of SPD. Because these

20 molecules are formed entirely from naturally occurring proteins, the production of an immune response (e.g., antibodies) to these fusion proteins is minimized. By deleting portions of the stalk region of the TNFSF proteins, additional constructs can be made which may be even less immunogenic.

25 **Example 2.**

Expression of human and murine CD40L-SPD in CHO cells.

The coding regions for the extracellular portion of human CD40L, human T147N-CD40L, an inactive mutant of CD40L, or murine CD40L were joined to the neck region of murine SPD, replacing the SPD CRD (Fig. 1). A CMV-driven

expression plasmid for the construct was co-transfected with a DHFR minigene into DNFR-deficient CHO cells. Following selection in nucleoside-free media, expressing CHO clones were amplified by culture in ascending doses of methotrexate. The resulting clones produced about 1-10 µg/mL of the fusion 5 protein over a 3 day period in media containing FBS.

Clones were adapted for growth as suspension cells in two types of serum-free media. Murine CHO-SPD produced in UltraCHO (BioWhittaker) was largely retained (about 60% as determined by ELISA) by a 1,000 kDa cutoff 10 ultrafiltration membrane (Pall Corp., Port Washington, NY), consistent with a large multimeric complex formed by the stacking of the SPD portion of the molecule. However, in CHO-S-SFM II (Life Technologies), nearly all ELISA-detectable murine CHO-SPD passed through a 100 kDa cutoff ultrafiltration membrane (Millipore), suggesting that the protein was either folding incorrectly 15 in this media or was being degraded by proteolysis. Consequently, the purification method was optimized for the spent UltraCHO media.

Example 3.

Purification of human and murine CD40L-SPD.

20 Purification procedures were developed for murine CD40L-SPD, but the same methods could be applied to human CD40L-SPD with minor modifications. Murine CD40L-SPD has a predicted m.w. of 49 kDa per chain, or about 600 kDa per 12-chain, cruciate molecule, the amino acid sequence predicts a pI of 9.10. Accordingly, conditioned media was concentrated by ultrafiltration through a 100 25 kDa cutoff filter, which also fractionates the sample on a size basis. After diafiltration into 50 mM bicine, pH 9.00 (also containing 1 mM EDTA added to inhibit metalloproteinases), the sample was applied to a variety of cationic exchange resins. Using Source 30S (Amersham-Pharmacia), most of the ELISA-detectable protein did not bind and was recovered in the flow-through. However,

as reported by Morris et al. {Morris}, Fractogel SO₃ 650M retained the protein. The retention by this tentacular resin and not by Source 30S suggests binding to positively charged residues that are not on the protein surface. Using a linear NaCl gradient, ELISA-detectable protein elutes at between 0.15-0.30 M NaCl under these conditions (Fig. 2). In selected experiments, the protein was further purified using a Superose 6 sizing column. Most of the ELISA-detectable protein eluted in the excluded volume, indicating an apparent m.w. of greater than 1,000 kDa (Fig. 3).

10 **Example 4.**

Activity of CD40L-SPD on human B cells.

Schultze *et al.* described a system using CD40L-expressing cells plus IL-4 and cyclosporin A (to inhibit T cell growth) as a means to grow very large numbers of B cells from a small sample of blood. Because CD40L activates these 15 B cells to express high levels of B7 molecules (CD80 and CD86), the proliferating B cells were effective in presenting peptide antigens and rival non-dividing dendritic cells as antigen-presenting cells (APCs) (36). To determine if the CD40L-SPD fusion protein could replace CD40L-expressing cells in this system, PBMC were cultured with CD40L-SPD in addition to IL-4 and cyclosporin A. 20 Under these conditions the cells grew to saturation density every three days. After three weeks, the cultures were almost entirely CD19+ B cells which express high levels of CD80 (Fig. 4). This indicates that CD40L-SPD can be used in *ex vivo* systems where a soluble yet effective form of CD40L is needed to stimulate cells for immunotherapeutic applications.

25

Example 5.

Activity of CD40L-SPD on murine B cells.

Resting murine B cells are particularly difficult to stimulate with most soluble forms of CD40L. Even with murine CD40L-CD8 fusion proteins, it is

necessary to crosslink the protein with antibodies against CD8 in order to achieve maximal proliferation in culture [Klauss, 1999]. Accordingly, resting murine B cells were negatively selected with immunomagnetic beads. As shown in Fig. 5, murine CD40L-SPD was as effective as anti-IgM antibody in driving B cells to 5 proliferate. This indicates that CD40L-SPD can mimic the multivalent interactions that occur when a responding cell comes in contact with CD40L-bearing activating cells.

Example 6.

10 Activity of CD40L-SPD on human macrophages and dendritic cells.

CD40L is a powerful stimulant for macrophages (reviewed in (28)) and dendritic cells (40). Accordingly, preparations of CD40L-SPD were added to monocyte-derived macrophages and the production of MIP-1 α was used as a measure of stimulation. As shown in Fig. 6, both human and murine CD40L-SPD 15 were able to stimulate macrophages, whereas the T147N-CD40L-SPD mutant was inactive as expected.

DISCUSSION

These examples define a new method of producing multimeric (i.e., many 20 trimers) of CD40L as a fusion protein with SPD. Also prepared and expressed were similar fusion proteins between murine RANKL/TRANCE (TNFSF11) or murine CD27L/CD70 (TNFSF7) joined to murine SPD (data not shown). This suggests that virtually all TNFSF members could be successfully produced as fusion proteins with SPD. Furthermore, it is also likely that other collectins 25 besides SPD could be used in these fusions, given the strong structural homologies between the CRDs of the collectins and the extracellular domains of TNFSF members [Shapiro] which can be substituted for these CRDs. Given the 17 known TNFSF members and 9 known collectins, at least 153 fusion protein combinations are possible.

SPD was selected for initially because it is a soluble homopolymer. Other collectins, such as surfactant protein A, have strong binding affinities to lipids and specific cell receptors. Although removal of the CRD abrogates much of this binding, it may be partially mediated by the neck region sequence, which the 5 fusion proteins retain. Accordingly, it would be expected that collectins other than SPD might confer different cell-binding and pharmacokinetic behaviors upon a fusion protein. For example, macrophages are known to take up and degrade whole SPD [Dong, 1998]. If a fusion protein other than SPD were used, the disposition of the fusion protein *in vivo* might be altered. Additionally, 10 metalloproteinases are known to degrade the collectin, C1q , so that a fusion with C1q may alter the degradation of the fusion protein. For example, because CD40L activates macrophages and other cells to produce metalloproteinases, which could potentially degrade the collagenous portion of SPD and other collectins. Cleavage of the collagenous stalk would then be expected to release 15 single-trimmers of CD40L, which could diffuse away from the original parent molecule, much like a slow-release formulation of a drug. Also, the membrane-proximal portion of CD40L has been retained in CD40L-SPD. This sequence also contains protease-susceptible amino acid sequences, which can be eliminated by mutagenesis to retard the cleavage of CD40L from the fusion protein. Mutations 20 in such proteinase cleavage site(s) would delay such cleavage and favor the local persistence of the CD40L stimulus.

CD40L-SPD is a large macromolecule (> 1,000 kDa), and the other TNFSF-collectin fusion proteins would be expected to be similarly large. For 25 native SPD, the aggregates that spontaneously form measure 100 nm in diameter. When injected into tissue, this large a complex would be expected to remain at the injection site for a prolonged period. Localization of the TNFSF-containing protein would also be expected to reduce any systemic toxicity caused by the release of free single-trimmers into the circulation. For example, soluble CD40L in

blood has been linked to disease activity in lupus, and this smaller molecule may even cross the glomerulus to cause damage to renal tubules [Kato and Kipps, J. Clin. Invest. Nov. 1999]. On the other hand, because CD40L induces the production of chemokines which attract immune cells [Kornbluth], T cells, 5 monocytes, and dendritic cells would be expected migrate to the site where CD40L-SPD was injected. This might be advantageous if CD40L-SPD were used as a vaccine adjuvant. In mice, soluble CD40L (sCD40LT) stimulates IgG1 production but not cytotoxic T lymphocytes (CTLs) [Wong, 1999]. Interestingly, the same protein that is expressed from an injected plasmid stimulates both a 10 strong antibody and CTL response [Gurunathan, 1998]. In the latter case, the plasmid would be expected to deliver a localized supply of CD40L, whereas the sCD40LT protein is free to diffuse away. Support for the localized use of CD40L in an adjuvant formulation is provided by a study using a plasmid expressing full-length membrane CD40L, which was very effective in stimulating both humoral 15 and CTL immune responses [Mendoza, 1997]. Similarly, injection of adenovirus expressing membrane CD40L has potent antitumor activity in mice [Kikuchi, 1999]. Similar considerations would likely apply to other fusion proteins between the TNFSF and collectins.

20 Finally, for immunostimulatory proteins, it is particularly important that the protein not be antigenic if repeated injections are needed. For example, vaccination with TNF- μ modified by the addition of short peptide sequences was able to induce the production of disease-modifying anti-TNF- μ autoantibodies [Dalum, 1999]. Because CD40L-SPD and other TNFSF-collectin fusion proteins 25 are formed from endogenous protein sequences (with the possible exception of the peptide sequence at the junction), the production of antibodies might not limit the effectiveness of repeated injections.

In conclusion, fusions between TNFSF members and collectins offer a

novel means of generating large protein complexes which can provide localized stimulation at an injection site. Because of the multimeric nature of the collectin backbone, such fusion proteins may mimic the multivalent ligand surface presented by the membrane forms of TNFSF members to TNFRSF-bearing 5 responding cells. Moreover, by limiting systemic toxicity while maintaining localized efficacy, such fusion proteins may have a role as vaccine adjuvants against infectious agents and tumors.

Table I
Ligands of the TNF Superfamily*

| <u>New Ligand Symbol</u> | <u>Other Names</u> | |
|--------------------------|---------------------------------------|-----------|
| <u>Genbank ID</u> | | |
| LTA | Lymphotoxin-, TNF- \square , TNFSF1 | X01393 |
| TNF | TNF- \square , TNFSF2 | X02910 |
| LTB | Lymphotoxin-, TNFSF3 | L11016 |
| TNFSF4 | OX-40L | D90224 |
| TNFSF5 | CD40L, CD154, Gp39, T-BAM | X67878 |
| TNFSF6 | FasL | U11821 |
| TNFSF7 | CD27L, CD70 | L08096 |
| TNFSF8 | CD30L | L09753 |
| TNFSF9 | 4-1BBL | U03398 |
| TNFSF10 | TRAIL, Apo-2L | U37518 |
| TNFSF11 | RANKL, TRANCE, OPGL, ODF | AF013171 |
| TNFSF12 | TWEAK, Apo-3L | AF030099 |
| TNFSF13 | APRIL | NM_003808 |
| TNFSF13B | BAFF, THANK, BLYS | AF136293 |
| TNFSF14 | LIGHT, HVEM-L | AF036581 |
| TNFSF15 | VEGI | AF039390 |
| TNFSF16 | unidentified | |
| TNFSF17 | unidentified | |
| TNFSF18 | AITRL, GITRL | AF125303 |

*(as of Nov. 1, 1999)

Known members of ligands in the TNF superfamily, taken from the Human
Gene Nomenclature Committee at

<http://www.gene.ucl.ac.uk/users/hester/tnftop.htm>

Table II
The Collectin Superfamily

| | |
|--------------------------------|----------------------|
| C1q | Pulmonary surfactant |
| Mannose-binding protein, MBL1 | protein D |
| Mannose-binding protein, MBL2 | conglutinin |
| Pulmonary surfactant protein A | collectin-43 |
| | CL-L1 |
| | ACRP30 |
| | Hib27 |

All collectins are formed as multimers of trimeric subunits, each containing a collagenous domain. The C-terminus of each collectin contains a CRD which binds carbohydrates and other ligands. Because of the tight similarities between

- 5 the known CRD structures and the extracellular domains of TNFSF members, it is likely that the CRD of any collectin could be replaced with the extracellular domain of any TNFSF member in a structurally compatible manner.

While the present invention has now been described in terms of certain
10 preferred embodiments, and exemplified with respect thereto, one skilled in the art will readily appreciate that various modifications, changes, omissions and substitutions may be made without departing from the spirit thereof. It is intended, therefore, that the present invention be limited solely by the scope of the following claims.

CLAIMS

What is claimed is:

5 1. A hybrid nucleotide sequence of no more than 1528 base pairs including a sequence defining a structural gene expressing a conjoined single strand of a multimeric TNFSF-SPD fusion protein, said structural gene having a nucleotide base sequence selected from members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5.

10

2. The DNA segment according to claim 1, wherein the structural gene comprises:

a segment expressing a single hybrid amino acid chain of TNFSF-SPD, said segment having

15

a first SPD nucleotide base sequence of SEQ ID NO 1, from base 32 to base 799, and

a second sequence, expressing a portion of TNFSF stalk, selected from members of the group consisting of SEQ ID NO 1, from base 800 to base 1444, SEQ ID NO 3, from base 800 to base 1528, and SEQ ID NO 5,

20

from base 800 to base 1441.

3. A recombinant DNA molecule comprising a vector operatively linked to an exogenous DNA segment defining a structural gene expressing a single amino acid chain of TNFSF-SPD, said structural gene having

25

a nucleotide base sequence selected from members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5, any functional equivalents and modifications thereof, and

an appropriate promoter for driving the expression of said structural gene in a compatible host organism.

4. The recombinant DNA molecule as described in claim 3 wherein said host organism is *E. coli*.

5 5. The recombinant DNA molecule as described in claim 3, wherein said host organism is a yeast.

6. The recombinant DNA molecule as described in claim 3, wherein said host organism is a higher plant or animal.

10

7. A multimeric TNFSF-SPD fusion protein comprising:
a plurality of polypeptide trimers,

i) a first trimer consisting of peptide strands of members of the TNF superfamily (TNFSF) of ligands, and

15

ii) a second trimer strand from a collectin molecule

each first trimer conjoined to a second polypeptide trimer strand from a collectin molecule, wherein said ligand strand is substituted for native carbohydrate recognition domains (CRD) of the collectin molecules,

20

said conjoined collectin strands covalently bound in parallel to each other, therein forming a multimeric fusion protein comprising a plurality of trimeric hybrid polypeptide strands radiating from a covalently bound center hub of the molecule, the free end of each trimeric radiating strand having a TNFSF moiety attached.

25

8. The multimeric fusion protein according to claim 6, wherein the TNFSF moiety is one selected from the group consisting of ligands LTA, TNF, LTB, and TNFSF4 to TNFSF 18 as in Table II, their functional equivalents, and

modifications thereof.

9. A method for preparing a CD40-SPD multimeric fusion polypeptide, comprising the steps of:

5. initiating a culture, in a nutrient medium, of prokaryotic or eukaryotic host cells transformed with a recombinant DNA molecule including an expression vector, appropriate for said cells, operatively linked to an exogenous DNA segment defining a structural gene for CD40-SPD ligand, said structural gene having a nucleotide base sequence of SEQ ID NO 1 from about base 32 to about
10 base 1444; and

maintaining said culture for a time period sufficient for said cells to express said multimeric molecule.

10. A method of producing a secreted, large, biologically active, multimeric tumor necrosis factor superfamily ligand fusion protein chimera that is highly immunogenic and not readily diffusible, comprising:

introducing into a host cell a first chimeric DNA construct including
a transcriptional promoter operatively linked to a first
secretory signal sequence, followed downstream by, and in proper
20 reading frame with

a first DNA sequence encoding a polypeptide chain of
a first TNFSF ligand requiring multimerization for biological
activity, joined to

25 a second DNA sequence encoding a collectin
polypeptide at the site where the collectin's CRD was
purposefully removed,

introducing into said host cell a second DNA construct including
a transcriptional promoter operably linked to a second
secretory signal sequence followed downstream by, and in

proper reading frame with,

a third DNA sequence encoding a second polypeptide chain of a second TNFSF ligand , joined to

5 a fourth DNA sequence encoding a collectin polypeptide , wherein the collectin's CRD was purposefully removed;

growing said host cell in an appropriate growth medium under physiological conditions to allow the secretion of a large multimerized polypeptide fusion protein, wherein

10 said first polypeptide chain of a TNFSF-SPD protein is bound by parallel bonding of the respective collectin domain trimer to

said second polypeptide chain of a different TNFSF-SPD polypeptide trimer, and wherein said multimerized polypeptide fusion protein exhibits biological activity characteristic of both membrane-attached TNFSFs; and

15 isolating said biologically active, multimerized TNFSF-SPD polypeptide fusion from said host cell.

11. The method according to claim 10, wherein the chimeric reactant compounds are humanized to guard against destruction by a potential human recipient's immune system.

12. A method of preparing a multimeric TNFSF-SPD ligand fusion protein, comprising:

25 preparing a first DNA segment coding for a strand of an exposed extracellular portion of TNFSF;

preparing a second DNA segment coding for a collectin polypeptide strand, wherein said collectin's CRD domain of the strand has been removed;

conjoining said first and second DNAs in proper reading frame, therein

creating a TNFSF-collectin DNA construct;
inserting said construct into an expression vector system;
introducing said vector system into an appropriate cell in culture under
suitable conditions;
5 harvesting and purifying spent medium from said culture; and
assaying for presence of multimeric TNFSF-collectin fusion protein.

13. A method for stimulating the immune response in potentially
immunocompetent cells using multimeric TNFSF fusion proteins, comprising:
10 contacting said cells with said multimeric TNFSF fusion proteins, wherein
said cells are induced to proliferate.

14. The method according to claim 15, wherein the cells are resting B cells.
15 15. A method for increasing antigenicity of cells, comprising:
contacting said cells with said multimeric TNFSF fusion proteins, wherein said
cells are tumor cells or HIV positive cells.




Figure 1




Figure 2

Figure 3



CD19 CYCHROME



CD19 CYCHROME



**Figure 4**

Figure 5



5/7





Figure 6

Figure 7



7/7

SEQUENCE LISTING

<110> Kornbluth, Richard S

<120> Multimeric forms of CD40L and other TNF family members

<130> TNFSF-collectin fusion proteins

<140> 60/111,471

<141> 1998-12-08

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 1552

<212> DNA

<213> Artificial Sequence

<220>

<221> 5'UTR

<222> (7)..(31)

<220>

<221> misc_feature

<222> (88)..(799)

<223> Mature murine surfactant protein D including hub region, collagenous portion, and neck, but excluding carbohydrate recognition domain (CRD)

<220>

<221> misc_feature

<222> (801)..(1546)

<223> Human CD40 ligand extracellular region, including stalk.

<220>

<221> sig_peptide

<222> (32)..(88)

<223> Signal peptide from murine surfactant protein D

<220>

<221> CDS
<222> (32)..(1444)

<220>

<223> Description of Artificial Sequence: Murine surfactant protein D (without the CRD) fused to the extracellular portion of human CD40L

<300>

<301> Spriggs, Melanie K.
Armitage, Richard J.
Strockbine, L
Clifford, K N.
Macduff, B M.
Sato, T A.
Maliszewski, C R.
Fanslow, William C.

<302> Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion.

<303> J. Exp. Med.

<304> 176

<305> 6

<306> 1543-1550

<307> 1992

<313> 801 TO 1600

<300>

<301> Motwani, M
White, R A.
<302> Mouse surfactant protein-D. cDNA cloning, characterization, and gene localization to chromosome 14.

<303> J. Immunol.

<304> 155

<305> 12

<306> 5671-5677

<307> 1995

<313> 32 TO 800

<400> 1

gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg
52

Met Leu Pro Phe Leu Ser Met

1

5

ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag
100
Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys
10 15 20

agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt
148
Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys
25 30 35

agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga
196
Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg
40 45 50 55

gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg
244
Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met
60 65 70

ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga
292
Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly
75 80 85

gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta
340
Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu
90 95 100

agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa
388
Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu
105 110 115

ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt
436
Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly
120 125 130 135

cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg
484
Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met
140 145 150

caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga
532
Gln Gly Ser Thr Gly Ala Lys Gly Ser Thr Gly Pro Lys Gly Glu Arg
155 160 165

ggt gcc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga
580
Gly Ala Pro Gly Val Gln Gly Ala Pro Gly Asn Ala Gly Ala Ala Gly
170 175 180

cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc
628
Pro Ala Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Ser Arg Gly Pro
185 190 195

cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa
676
Pro Gly Leu Lys Gly Asp Arg Gly Val Pro Gly Asp Arg Gly Ile Lys
200 205 210 215

ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag
724
Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu
220 225 230

gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat
772
Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr
235 240 245

cag aaa gct gca ttg ttc cct gat ggc cat aga agg ttg gac aag ata
820
Gln Lys Ala Ala Leu Phe Pro Asp Gly His Arg Arg Leu Asp Lys Ile
250 255 260

gaa gat gaa agg aat ctt cat gaa gat ttt gta ttc atg aaa acg ata
868
Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met Lys Thr Ile

265

270

275

cag aga tgc aac aca gga gaa aga tcc tta tcc tta ctg aac tgt gag
916 Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu Asn Cys Glu
280 285 290 295

gag att aaa agc cag ttt gaa ggc ttt gtg aag gat ata atg tta aac
964 Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile Met Leu Asn
300 305 310

aaa gag gag acg aag aaa gaa aac agc ttt gaa atg caa aaa ggt gat
1012 Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln Lys Gly Asp
315 320 325

cag aat cct caa att gcg gca cat gtc ata agt gag gcc agc agt aaa
1060 Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala Ser Ser Lys
330 335 340

aca aca tct gtg tta cag tgg gct gaa aaa gga tac tac acc atg agc
1108 Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr Thr Met Ser
345 350 355

aac aac ttg gta acc ctg gaa aat ggg aaa cag ctg acc gtt aaa aga
1156 Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr Val Lys Arg
360 365 370 375

caa gga ctc tat tat atc tat gcc caa gtc acc ttc tgt tcc aat cgg
1204 Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys Ser Asn Arg
380 385 390

gaa gct tcg agt caa gct cca ttt ata gcc agc ctc tgc cta aag tcc
1252 Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys Leu Lys Ser
395 400 405

ccc ggt aga ttc gag aga atc tta ctc aga gct gca aat acc cac agt
1300

Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn Thr His Ser
410 415 420

tcc gcc aaa cct tgc ggg caa caa tcc att cac ttg gga gga gta ttt
1348

Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly Gly Val Phe
425 430 435

gaa ttg caa cca ggt gct tcg gtg ttt gtc aat gtg act gat cca agc
1396

Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr Asp Pro Ser
440 445 450 455

caa gtg agc cat ggc act ggc ttc acg tcc ttt ggc tta ctc aaa ctc
1444

Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu Leu Lys Leu
460 465 470

tgaacagtgt caccttgcag gctgtggtgg agctgacgct gggagtcattc ataatacagc
1504

acaggcttaa gcccaattat acactccaag gcatgtagaa ctggtagcc
1552

<210> 2

<211> 471

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Murine
surfactant protein D (without the CRD) fused to
the extracellular portion of human CD40L

<400> 2

Met Leu Pro Phe Leu Ser Met Leu Val Leu Leu Val Gln Pro Leu Gly
1 5 10 15

Asn Leu Gly Ala Glu Met Lys Ser Leu Ser Gln Arg Ser Val Pro Asn
20 25 30

Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly

35

40

45

Arg Asp Gly Arg Asp Gly Arg Glu Gly Pro Arg Gly Glu Lys Gly Asp
50 55 60

Pro Gly Leu Pro Gly Pro Met Gly Leu Ser Gly Leu Gln Gly Pro Thr
65 70 75 80

Gly Pro Val Gly Pro Lys Gly Glu Asn Gly Ser Ala Gly Glu Pro Gly
85 90 95

Pro Lys Gly Glu Arg Gly Leu Ser Gly Pro Pro Gly Leu Pro Gly Ile
100 105 110

Pro Gly Pro Ala Gly Lys Glu Gly Pro Ser Gly Lys Gln Gly Asn Ile
115 120 125

Gly Pro Gln Gly Lys Pro Gly Pro Lys Gly Glu Ala Gly Pro Lys Gly
130 135 140

Glu Val Gly Ala Pro Gly Met Gln Gly Ser Thr Gly Ala Lys Gly Ser
145 150 155 160

Thr Gly Pro Lys Gly Glu Arg Gly Ala Pro Gly Val Gln Gly Ala Pro
165 170 175

Gly Asn Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Gln Gly
180 185 190

Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val
195 200 205

Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala
210 215 220

Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu
225 230 235 240

Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly
245 250 255

His Arg Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp
260 265 270

Phe Val Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser
275 280 285

Leu Ser Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe
290 295 300

Val Lys Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser
305 310 315 320

Phe Glu Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val
325 330 335

Ile Ser Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu
340 345 350

Lys Gly Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly
355 360 365

Lys Gln Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln
370 375 380

Val Thr Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile
385 390 395 400

Ala Ser Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu
405 410 415

Arg Ala Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser
420 425 430

Ile His Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe
435 440 445

Val Asn Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr
450 455 460

Ser Phe Gly Leu Leu Lys Leu
465 470

<210> 3

<211> 1574

<212> DNA

<213> Artificial Sequence

<220>

<221> 5'UTR

<222> (7)..(31)

<223> 5' UTR taken from rat sequence for surfactant protein D

<220>

<221> sig_peptide

<222> (32)..(88)

<223> Signal peptide from murine surfactant protein D

<220>

<221> CDS

<222> (32)..(1534)

<220>

<221> misc_feature

<222> (32)..(800)

<223> Murine surfactant protein D including hub region, collagenous portion, and neck, but excluding carbohydrate recognition domain (CRD)

<220>

<221> misc_feature

<222> (801)..(1534)

<223> Murine RANKL/TRANCE extracellular region, including stalk

<300>

<301> Motwani, M

White, R A.

Guo, N

Dowler, L L.

Tauber, A I.

Motwani, M

<302> Mouse surfactant protein-D. cDNA cloning, characterization, and gene localization to chromosome 14.

<303> J. Immunol.

<304> 155
<305> 12
<306> 5671-5677
<307> 1995
<313> 32 TO 800

<300>

<301> Anderson, D M.
Maraskovsky, E
Billingsley, W L.
Dougall, W C.

<302> A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

<303> Nature
<304> 390
<305> 6656
<306> 175-179
<307> 1997
<313> 801 TO 1534

<400> 3

gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg
52

Met Leu Pro Phe Leu Ser Met
1 5

ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag
100

Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys
10 15 20

agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt
148

Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys
25 30 35

agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga
196

Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg
40 45 50 55

gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg
244

Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met
60 65 70

ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga
292

Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly
75 80 85

gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta
340

Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu
90 95 100

agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa
388

Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu
105 110 115

ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt
436

Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly
120 125 130 135

cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg
484

Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met
140 145 150

caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga
532

Gln Gly Ser Thr Gly Ala Lys Gly Ser Thr Gly Pro Lys Gly Glu Arg
155 160 165

ggt gcc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga
580

Gly Ala Pro Gly Val Gln Gly Ala Pro Gly Asn Ala Gly Ala Ala Gly
170 175 180

cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc
628

Pro Ala Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Ser Arg Gly Pro
185 190 195

cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa
676
Pro Gly Leu Lys Gly Asp Arg Gly Val Pro Gly Asp Arg Gly Ile Lys
200 205 210 215
ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag
724
Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu
220 225 230
gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat
772
Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr
235 240 245
cag aaa gct gca ttg ttc cct gat ggt cga gcg cag atg gat cct aac
820
Gln Lys Ala Ala Leu Phe Pro Asp Gly Arg Ala Gln Met Asp Pro Asn
250 255 260
aga ata tca gaa gac agc act cac tgc ttt tat aga atc ctg aga ctc
868
Arg Ile Ser Glu Asp Ser Thr His Cys Phe Tyr Arg Ile Leu Arg Leu
265 270 275
cat gaa aac gca ggt ttg cag gac tcg act ctg gag agt gaa gac aca
916
His Glu Asn Ala Gly Leu Gln Asp Ser Thr Leu Glu Ser Glu Asp Thr
280 285 290 295
cta cct gac tcc tgc agg agg atg aaa caa gcc ttt cag ggg gcc gtg
964
Leu Pro Asp Ser Cys Arg Arg Met Lys Gln Ala Phe Gln Gly Ala Val
300 305 310
cag aag gaa ctg caa cac att gtg ggg cca cag cgc ttc tca gga gct
1012
Gln Lys Glu Leu Gln His Ile Val Gly Pro Gln Arg Phe Ser Gly Ala
315 320 325
cca gct atg atg gaa ggc tca tgg ttg gat gtg gcc cag cga ggc aag
1060
Pro Ala Met Met Glu Gly Ser Trp Leu Asp Val Ala Gln Arg Gly Lys

330

335

340

cct gag gcc cag cca ttt gca cac ctc acc atc aat gct gcc agc atc
1108

Pro Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile
345 350 355

cca tcg ggt tcc cat aaa gtc act ctg tcc tct tgg tac cac gat cga
1156

Pro Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg
360 365 370 375

ggc tgg gcc aag atc tct aac atg acg tta agc aac gga aaa cta agg
1204

Gly Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg
380 385 390

gtt aac caa gat ggc ttc tat tac ctg tac gcc aac att tgc ttt cgg
1252

Val Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg
395 400 405

cat cat gaa aca tcg gga agc gta cct aca gac tat ctt cag ctg atg
1300

His His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met
410 415 420

gtg tat gtc gtt aaa acc agc atc aaa atc cca agt tct cat aac ctg
1348

Val Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu
425 430 435

atg aaa gga ggg agc acg aaa aac tgg tcg ggc aat tct gaa ttc cac
1396

Met Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His
440 445 450 455

ttt tat tcc ata aat gtt ggg gga ttt ttc aag ctc cga gct ggt gaa
1444

Phe Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu
460 465 470

gaa att agc att cag gtg tcc aac cct tcc ctg ctg gat ccg gat caa
1492

Glu Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln
475 480 485

gat gcg acg tac ttt ggg gct ttc aaa gtt cag gac ata gac
1534

Asp Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp
490 495 500

tgagactcat ttcgtggaac attagcggcc gctaaactat
1574

<210> 4

<211> 501

<212> PRT

<213> Artificial Sequence

<400> 4

Met Leu Pro Phe Leu Ser Met Leu Val Leu Leu Val Gln Pro Leu Gly
1 5 10 15

Asn Leu Gly Ala Glu Met Lys Ser Leu Ser Gln Arg Ser Val Pro Asn
20 25 30

Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly
35 40 45

Arg Asp Gly Arg Asp Gly Arg Glu Gly Pro Arg Gly Glu Lys Gly Asp
50 55 60

Pro Gly Leu Pro Gly Pro Met Gly Leu Ser Gly Leu Gln Gly Pro Thr
65 70 75 80

Gly Pro Val Gly Pro Lys Gly Glu Asn Gly Ser Ala Gly Glu Pro Gly
85 90 95

Pro Lys Gly Glu Arg Gly Leu Ser Gly Pro Pro Gly Leu Pro Gly Ile
100 105 110

Pro Gly Pro Ala Gly Lys Glu Gly Pro Ser Gly Lys Gln Gly Asn Ile
115 120 125

Gly Pro Gln Gly Lys Pro Gly Pro Lys Gly Glu Ala Gly Pro Lys Gly
130 135 140

Glu Val Gly Ala Pro Gly Met Gln Gly Ser Thr Gly Ala Lys Gly Ser
145 150 155 160

Thr Gly Pro Lys Gly Glu Arg Gly Ala Pro Gly Val Gln Gly Ala Pro
165 170 175

Gly Asn Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Gln Gly
180 185 190

Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val
195 200 205

Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala
210 215 220

Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu
225 230 235 240

Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly
245 250 255

Arg Ala Gln Met Asp Pro Asn Arg Ile Ser Glu Asp Ser Thr His Cys
260 265 270

Phe Tyr Arg Ile Leu Arg Leu His Glu Asn Ala Gly Leu Gln Asp Ser
275 280 285

Thr Leu Glu Ser Glu Asp Thr Leu Pro Asp Ser Cys Arg Arg Met Lys
290 295 300

Gln Ala Phe Gln Gly Ala Val Gln Lys Glu Leu Gln His Ile Val Gly
305 310 315 320

Pro Gln Arg Phe Ser Gly Ala Pro Ala Met Met Glu Gly Ser Trp Leu
325 330 335

Asp Val Ala Gln Arg Gly Lys Pro Glu Ala Gln Pro Phe Ala His Leu
340 345 350

Thr Ile Asn Ala Ala Ser Ile Pro Ser Gly Ser His Lys Val Thr Leu
355 360 365

Ser Ser Trp Tyr His Asp Arg Gly Trp Ala Lys Ile Ser Asn Met Thr
370 375 380

Leu Ser Asn Gly Lys Leu Arg Val Asn Gln Asp Gly Phe Tyr Tyr Leu
385 390 395 400

Tyr Ala Asn Ile Cys Phe Arg His His Glu Thr Ser Gly Ser Val Pro
405 410 415

Thr Asp Tyr Leu Gln Leu Met Val Tyr Val Val Lys Thr Ser Ile Lys
420 425 430

Ile Pro Ser Ser His Asn Leu Met Lys Gly Gly Ser Thr Lys Asn Trp
435 440 445

Ser Gly Asn Ser Glu Phe His Phe Tyr Ser Ile Asn Val Gly Gly Phe
450 455 460

Phe Lys Leu Arg Ala Gly Glu Glu Ile Ser Ile Gln Val Ser Asn Pro
465 470 475 480

Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr Tyr Phe Gly Ala Phe Lys
485 490 495

Val Gln Asp Ile Asp
500

<210> 5
<211> 1477
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Murine
surfactant protein D (except CRD) fused to the
extracellular domain of murine CD40 ligand

<220>

<221> 5'UTR
<222> (7)..(31)
<223> 5' UTR from rat surfactant protein D

<220>
<221> sig_peptide
<222> (32)..(88)
<223> Signal peptide from murine surfactant protein D

<220>
<221> CDS
<222> (32)..(1441)

<220>
<221> misc_recomb
<222> (88)..(799)
<223> Mature murine surfactant protein D including hub region, collagenous portion, and neck, but excluding carbohydrate recognition domain (CRD)

<220>
<221> misc_feature
<222> (800)..(1441)
<223> Murine CD40 ligand extracellular region, including stalk

<300>
<301> Motwani, M
White, R A.
Guo, N
Dowler, L L.
Tauber, A I.
Motwani, M
<302> Mouse surfactant protein-D. cDNA cloning, characterization, and gene localization to chromosome 14.
<303> J. Immunol.
<304> 155
<305> 12
<306> 5671-5677
<307> 1995
<313> 32 TO 800

<300>
<301> Armitage, R
Fanslow, W
Sato, T A.
Clifford, K N.
<302> Molecular and biological characterization of a murine
ligand for CD40
<303> Nature
<304> 357
<305> 6373
<306> 80-82
<307> 1992
<313> 801 TO 1441

<400> 5
gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg
52
Met Leu Pro Phe Leu Ser Met
1 5

ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag
100
Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu C_y Ala Glu Met Lys
10 15 20

agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt
148
Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys
25 30 35

agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga
196
Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg
40 45 50 55

gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg
244
Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met
60 65 70

ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga
292
Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly

75

80

85

gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta
340

Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu
90 95 100

agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa
388

Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu
105 110 115

ggc ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt
436

Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly
120 125 130 135

cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg
484

Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met
140 145 150

caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga
532

Gln Gly Ser Thr Gly Ala Lys Gly Ser Thr Gly Pro Lys Gly Glu Arg
155 160 165

ggc ccc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga
580

Gly Ala Pro Gly Val Gln Gly Ala Pro Gly Asn Ala Gly Ala Ala Gly
170 175 180

cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc
628

Pro Ala Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Ser Arg Gly Pro
185 190 195

cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa
676

Pro Gly Leu Lys Gly Asp Arg Gly Val Pro Gly Asp Arg Gly Ile Lys
200 205 210 215

ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag

724

Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu
220 225 230

gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat
772

Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr
235 240 245

cag aaa gct gca ttg ttc cct gat ggc cat aga aga ttg gat aag gtc
820

Gln Lys Ala Ala Leu Phe Pro Asp Gly His Arg Arg Leu Asp Lys Val
250 255 260

gaa gag gaa gta aac ctt cat gaa gat ttt gta ttc ata aaa aag cta
868

Glu Glu Glu Val Asn Leu His Glu Asp Phe Val Phe Ile Lys Lys Leu
265 270 275

aag aga tgc aac aaa gga gaa gga tct tta tcc ttg ctg aac tgt gag
916

Lys Arg Cys Asn Lys Gly Glu Gly Ser Leu Ser Leu Leu Asn Cys Glu
280 285 290 295

gag atg aga agg caa ttt gaa gac ctt gtc aag gat ata acg tta aac
964

Glu Met Arg Arg Gln Phe Glu Asp Leu Val Lys Asp Ile Thr Leu Asn
300 305 310

aaa gaa gag aaa aaa gaa aac agc ttt gaa atg caa aga ggt gat gag
1012

Lys Glu Glu Lys Lys Glu Asn Ser Phe Glu Met Gln Arg Gly Asp Glu
315 320 325

gat cct caa att gca gca cac gtt gta agc gaa gcc aac agt aat gca
1060

Asp Pro Gln Ile Ala Ala His Val Val Ser Glu Ala Asn Ser Asn Ala
330 335 340

gca tcc gtt cta cag tgg gcc aag aaa gga tat tat acc atg aaa agc
1108

Ala Ser Val Leu Gln Trp Ala Lys Lys Gly Tyr Tyr Thr Met Lys Ser

345

350

355

aac ttg gta atg ctt gaa aat ggg aaa cag ctg acg gtt aaa aga gaa
1156

Asn Leu Val Met Leu Glu Asn Gly Lys Gln Leu Thr Val Lys Arg Glu
360 365 370 375

gga ctc tat tat gtc tac act caa gtc acc ttc tgc tct aat cgg gag
1204

Gly Leu Tyr Tyr Val Tyr Thr Gln Val Thr Phe Cys Ser Asn Arg Glu
380 385 390

cct tcg agt caa cgc cca ttc atc gtc ggc ctc tgg ctg aag ccc agc
1252

Pro Ser Ser Gln Arg Pro Phe Ile Val Gly Leu Trp Leu Lys Pro Ser
395 400 405

att gga tct gag aga atc tta ctc aag gcg gca aat acc cac agt tcc
1300

Ile Gly Ser Glu Arg Ile Leu Leu Lys Ala Ala Asn Thr His Ser Ser
410 415 420

tcc cag ctt tgc gag cag cag tct gtt cac ttg ggc gga gtg ttt gaa
1348

Ser Gln Leu Cys Glu Gln Gln Ser Val His Leu Gly Gly Val Phe Glu
425 430 435

tta caa gct ggt gct tct gtg ttt gtc aac gtg act gaa gca agc caa
1396

Leu Gln Ala Gly Ala Ser Val Phe Val Asn Val Thr Glu Ala Ser Gln
440 445 450 455

gtg atc cac aga gtt ggc ttc tca tct ttt ggc tta ctc aaa ctc
1441

Val Ile His Arg Val Gly Phe Ser Ser Phe Gly Leu Leu Lys Leu
460 465 470

tgaacagtgc gctgtcctag gctgcagcag ggtacc
1477

<210> 6

<211> 470

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Murine
surfactant protein D (except CRD) fused to the
extracellular domain of murine CD40 ligand

<400> 6

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Leu | Pro | Phe | Leu | Ser | Met | Leu | Val | Leu | Leu | Val | Gln | Pro | Leu | Gly |
| 1 | | | | 5 | | | | | 10 | | | | 15 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Leu | Gly | Ala | Glu | Met | Lys | Ser | Leu | Ser | Gln | Arg | Ser | Val | Pro | Asn |
| | | | | | 20 | | | | 25 | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Cys | Thr | Leu | Val | Met | Cys | Ser | Pro | Thr | Glu | Asn | Gly | Leu | Pro | Gly |
| | | | | | 35 | | | 40 | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Asp | Gly | Arg | Asp | Gly | Arg | Glu | Gly | Pro | Arg | Gly | Glu | Lys | Gly | Asp |
| | | | | | | 50 | | 55 | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Gly | Leu | Pro | Gly | Pro | Met | Gly | Leu | Ser | Gly | Leu | Gln | Gly | Pro | Thr |
| | | | | | | 65 | | 70 | | | 75 | | | 80 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Pro | Val | Gly | Pro | Lys | Gly | Glu | Asn | Gly | Ser | Ala | Gly | Glu | Pro | Gly |
| | | | | | 85 | | | | 90 | | | | 95 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Lys | Gly | Glu | Arg | Gly | Leu | Ser | Gly | Pro | Pro | Gly | Leu | Pro | Gly | Ile |
| | | | | | | 100 | | | 105 | | | | 110 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Gly | Pro | Ala | Gly | Lys | Glu | Gly | Pro | Ser | Gly | Lys | Gln | Gly | Asn | Ile |
| | | | | | | 115 | | 120 | | | | 125 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Pro | Gln | Gly | Lys | Pro | Gly | Pro | Lys | Gly | Glu | Ala | Gly | Pro | Lys | Gly |
| | | | | | | 130 | | 135 | | | | 140 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Val | Gly | Ala | Pro | Gly | Met | Gln | Gly | Ser | Thr | Gly | Ala | Lys | Gly | Ser |
| | | | | | | 145 | | 150 | | | 155 | | | 160 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Gly | Pro | Lys | Gly | Glu | Arg | Gly | Ala | Pro | Gly | Val | Gln | Gly | Ala | Pro |
| | | | | | | 165 | | | 170 | | | | 175 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Asn | Ala | Gly | Ala | Ala | Gly | Pro | Ala | Gly | Pro | Ala | Gly | Pro | Gln | Gly |
| | | | | | | 180 | | | 185 | | | | 190 | | |

Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val
195 200 205

Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala
210 215 220

Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu
225 230 235 240

Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly
245 250 255

His Arg Arg Leu Asp Lys Val Glu Glu Val Asn Leu His Glu Asp
260 265 270

Phe Val Phe Ile Lys Lys Leu Lys Arg Cys Asn Lys Gly Glu Gly Ser
275 280 285

Leu Ser Leu Leu Asn Cys Glu Glu Met Arg Arg Gln Phe Glu Asp Leu
290 295 300

Val Lys Asp Ile Thr Leu Asn Lys Glu Glu Lys Lys Glu Asn Ser Phe
305 310 315 320

Glu Met Gln Arg Gly Asp Glu Asp Pro Gln Ile Ala Ala His Val Val
325 330 335

Ser Glu Ala Asn Ser Asn Ala Ala Ser Val Leu Gln Trp Ala Lys Lys
340 345 350

Gly Tyr Tyr Thr Met Lys Ser Asn Leu Val Met Leu Glu Asn Gly Lys
355 360 365

Gln Leu Thr Val Lys Arg Glu Gly Leu Tyr Tyr Val Tyr Thr Gln Val
370 375 380

Thr Phe Cys Ser Asn Arg Glu Pro Ser Ser Gln Arg Pro Phe Ile Val
385 390 395 400

Gly Leu Trp Leu Lys Pro Ser Ile Gly Ser Glu Arg Ile Leu Leu Lys
405 410 415

Ala Ala Asn Thr His Ser Ser Ser Gln Leu Cys Glu Gln Gln Ser Val

420

425

430

His Leu Gly Gly Val Phe Glu Leu Gln Ala Gly Ala Ser Val Phe Val
435 440 445

Asn Val Thr Glu Ala Ser Gln Val Ile His Arg Val Gly Phe Ser Ser
450 455 460

Phe Gly Leu Leu Lys Leu
465 470

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/07380

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 14/00; A61K 38/00
 US CL : 435/69.1; 530/324; 514/2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 435/69.1; 530/324; 514/2; 536/23.5, 435/455

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | GIRES, O. et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. October 1999, Vol. 16, No. 20, pages 6131-6140, especially page 6131. | 1-15 |
| A | PISON, U. et al. Host defence capacities of pulmonary surfactant: evidence for 'non-surfactant' functions of the surfactant system. Eur. J. Clin. Inv. September 1994, Vol. 24, No. 9, pages 586-599. | 1-15 |

 Further documents are listed in the continuation of Box C.

See patent family annex.

| | | |
|---|-----|--|
| • Special categories of cited documents: | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "E" earlier application or patent published on or after the international filing date | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" | document member of the same patent family |
| "O" document referring to an oral disclosure, use, exhibition or other means | | |
| "P" document published prior to the international filing date but later than the priority date claimed | | |

Date of the actual completion of the international search

26 July 2000 (26.07.2000)

Date of mailing of the international search report

18 SEP 2000

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Eyler Yvonne

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/07380

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.: 1-12
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
These claims are drawn to polypeptides and nucleic acids, but no computer-readable sequence information has been submitted. The search for these claims was therefore based on text alone.

3. Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

| |
|--------------------------|
| <input type="checkbox"/> |
| <input type="checkbox"/> |

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/07380

Continuation of B. FIELDS SEARCHED Item 3: STN, EAST
search terms: TNF, CD40L, collectin, multimer

THIS PAGE BLANK (USPTO)